The Voss Operation in Osteoarthritis of the Hip

Kollberg, Gösta; Lundholm, Gunnar

doi:10.3109/17453676508989374

Cited by 5 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1955 Voss [ 18 , 19 ] described a surgical procedure for the treatment of hip osteoarthritis, the so-called temporary hanging hip , entirely based on a new principle. In his opinion, the most important factor was that the muscles around the joint were in a state of increased tension; for this reason, the articular cartilage is put under abnormal pressure causing a so-called osteoarthrosis pressure .…”

Section: Discussionmentioning

confidence: 99%

“…It is known that BoNT-A is used for treatment of spasticity of the hip adductors and injections of BoNT-A have been used as an adjunctive measure to prevent or delay lateral migration of the femoral head in children with cerebral palsy [ 16 , 17 ]. It is hypothesized that BoNT-A injection into selected muscles involved in hip movements will reduce the pressure transferred by the femoral head against the acetabulum, as is achieved with the Voss operation [ 18 , 19 ]. This reduction in pressure aims to break, in an efficient and lasting manner if periodically treated, the vicious cycle induced by the combination of pain–contraction and contraction–pain.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study

Eleopra

Rinaldo

Lettieri

et al. 2018

Toxins

View full text Add to dashboard Cite

Hip Osteoarthritis (OA) causes pain and disability. Here we evaluate abobotulinumtoxinA (Dysport®) (AboBoNT-A) injections versus placebo as a novel treatment option to improve hip range of motion, pain and quality of life. This prospective randomized double-blind multicenter study (EudraCT # 2012-004890-25) recruited 46 outpatients with hip OA who were randomized 2:1 to the Treatment Group (TG; 31 subjects), or the Placebo Group (PG; 15 subjects). The TG received 400 U of AboBoNT-A injected into the adductor muscles, and the PG received placebo solution. The primary endpoints were the difference in Harris Hip Score (HHS) and Visual Analogic Scale for pain (VAS) at Week 4 between groups (TG vs. PG). Secondary endpoints were the change from baseline in HHS, VAS pain, Medical Research Council scale for muscle strength (MRC) and Short Form scale (SF-36) scores. In TG at Week 4, the HHS and VAS score were significantly improved compared to PG, and pairwise assessments showed significant improvements in HSS and VAS pain at each time point compared to baseline for TG. No significant changes were observed in MRC and SF-36 over time, though SF-36 showed a positive trend. There were no significant differences from baseline in the PG. No adverse events were detected in either treatment group. AboBoNT-A injections in hip OA improve range of motion and pain without any significant side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study

Eleopra

Rinaldo

Lettieri

et al. 2018

Toxins

View full text Add to dashboard Cite

show abstract

“…Non-prosthetic surgical treatments include partial or complete tenotomies of adductors and muscles inserted in the anterior iliac spine, which reduce muscle tension and mechanical stress between the acetabulum and the femoral head (Voss surgery). Given that botulinum toxin type A (BoNT-A) causes a chemical limited and transient denervation with subsequent flaccid paralysis of the injected striated muscle, which ultimately produces an effect that is similar to that of said technique by applying it only to the adductors and iliac portion of the iliac psoas 11 .…”

Section: Introductionmentioning

confidence: 99%

Osteoarthritis of the hip conservative treatment with type A botulinum toxin

Durán-Hernández

Soto-Rodríguez²,

Allen-Bobadilla

et al. 2023

GMM

View full text Add to dashboard Cite

The diagnosis of hip OA follows the 1991 American College of Rheumatology (ACR) guidelines and is addressed through history and physical examination, as well laboratory and radiographic examinations. In the algorithm, hip pain is taken into account plus two of the following criteria: 1) erythrocyte sedimentation rate < 20 mm/hour, 2) femoral or acetabular osteophytes and 3) narrowing of the upper, axial and/or medial joint space 7 . OA severity assessment is carried out using the Kellgren and Lawrence radiological scale proposed in 1957, which considers four grades of severity with a progressive increase in joint compromise (Table 1).OA was previously considered a degenerative disease and exclusive to articular cartilage but, currently, it is assumed as a chronic, low-grade inflammatory condition that fully affects the joint 8 . There are three main factors that participate in this process: the

show abstract

“…Dentro de los tratamientos quirúrgicos no protésicos se encuentran las tenotomías parciales o completas de aductores y músculos insertados en la espina ilíaca anterior, con lo que se logra disminuir la tensión muscular y el estrés mecánico entre el acetábulo y la cabeza femoral (cirugía de Voss). Dado que la toxina botulínica tipo A (BoNT-A) provoca una denervación química, delimitada y transitoria con la subsecuente parálisis flácida del músculo estriado inyectado, lo que se logra entonces es un efecto similar al de dicha técnica aplicándolo solo en los aductores y la porción ilíaca del psoas ilíaco 11 .…”

Section: Introductionunclassified

Tratamiento conservador de la osteoartrosis de cadera con toxina botulínica tipo A

Durán-Hernández

Soto-Rodríguez

Allen-Bobadilla

et al. 2019

GMM

View full text Add to dashboard Cite

La osteoartritis de cadera es una enfermedad articular inflamatoria de bajo grado y etiología múltiple que tiene un manejo conservador limitado y poco explorado. La aplicación de toxina botulínica tipo A (BoNT-A) produce en el músculo aplicado una parálisis flácida temporal, delimitable y reversible, que aplicada de manera estratégica logra liberar estrés mecánico y dolor. Objetivo: Evaluar el efecto en la percepción de dolor, funcionalidad y rigidez y los cambios en la flexión, rotación interna y externa, antes y 90 días después de la aplicación de BoNT-A. Métodos: Estudio clínico, experimental, longitudinal, abierto, con un total de 35 pacientes y 45 caderas tratadas. Se aplicó BoNT-A de 500 U en músculos ilíaco, músculo aductorbrevis y longus. Resultados: Se utilizó la prueba de Wilcoxon comparando los puntajes de evaluación en los días 0 a 90 observando disminución significativa del dolor referido (p < 0.0001), rigidez (p < 0.002), mejoró la función percibida (p < 0.001) y los arcos de movilidad: flexión, rotación interna y externa (p < 0.0001). Conclusiones: El tratamiento con BoNT-A otorga una opción conservadora y segura para el manejo de los síntomas y restricción física causada por la OA de cadera.

show abstract

The Voss Operation in Osteoarthritis of the Hip

Cited by 5 publications

References 3 publications

AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study

AbobotulinumtoxinA: A New Therapy for Hip Osteoarthritis. A Prospective Randomized Double-Blind Multicenter Study

Osteoarthritis of the hip conservative treatment with type A botulinum toxin

Tratamiento conservador de la osteoartrosis de cadera con toxina botulínica tipo A

Contact Info

Product

Resources

About